These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 13906466)

  • 1. Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macaca mulatta.
    HENNEBERG G; DRESCHER J; GODGLUECK G; GRUETZNER L
    Am J Hyg; 1962 Jan; 75():44-55. PubMed ID: 13906466
    [No Abstract]   [Full Text] [Related]  

  • 2. Further investigations on the immunogenic activity of aqueous and aluminum oxide adsorbed inactivated poliovirus vaccines in Macaca mulatta.
    Drescher J; Grützner L; Godglück G
    Am J Epidemiol; 1967 May; 85(3):413-23. PubMed ID: 4960865
    [No Abstract]   [Full Text] [Related]  

  • 3. [The potentiation of vaccines by aluminum oxide adsorption. 2. Aluminum oxide-poliomyelitis-diphtheria-tetanus vaccine].
    GRAFE A; KUHN RB
    Arzneimittelforschung; 1962 Apr; 12():392-5. PubMed ID: 13900987
    [No Abstract]   [Full Text] [Related]  

  • 4. The safety test for poliomyelitis vaccine. III. Comparative sensitivity of rhesus and vervet monkeys to poliovirus.
    VAN HOOSIER GL; BARON S; KIRSCHSTEIN RL; ABINANTI FR
    Am J Hyg; 1962 Jan; 75():86-9. PubMed ID: 13924586
    [No Abstract]   [Full Text] [Related]  

  • 5. [The potentiation of vaccines by aluminum oxide adsorption. 1. Aluminum oxide-poliovaccine].
    GRAFE A; KUHN RB
    Arzneimittelforschung; 1962 Jan; 12():33-7. PubMed ID: 13900986
    [No Abstract]   [Full Text] [Related]  

  • 6. Complement-fixing antigens of living and inactivated poliovirus. II. Complement-fixing activity of poliomyelitis vaccine and its relation to immunogenic potency.
    WARREN J; HARE JD; GOLDMAN C
    Am J Public Health Nations Health; 1959 Jan; 49(1):53-61. PubMed ID: 13617534
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurovirulence of attenuated type 1 poliovirus vaccine strains after intramuscular inoculation of rhesus monkeys.
    KIRSCHSTEIN R; BARON S; BORMAN GS; MURRAY R; PERKINS FT; HOTTLE G
    Virology; 1960 May; 11():300-2. PubMed ID: 14409387
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of guinea pigs in tests for immunogenic capacity of poliomyelitis virus preparations.
    GARD S; WESSLEN T; FAGRAEUS A; SVEDMYR A; OLIN G
    Arch Gesamte Virusforsch; 1956; 6(5):401-11. PubMed ID: 13340710
    [No Abstract]   [Full Text] [Related]  

  • 9. Small-scale trial with Sabin attenuated type 1 poliovirus vaccine in a semi-closed community.
    HOSKINS JM; HOBSON D; UDALL V; MADLAND T; GOFFE AP; STUART-HARRIS CH; HERZOG EG
    Br Med J; 1962 Mar; 1(5280):747-53. PubMed ID: 14449180
    [No Abstract]   [Full Text] [Related]  

  • 10. Live poliovirus vaccine for oral use.
    FERGUSON JK
    Can J Public Health; 1962 Apr; 53():135-42. PubMed ID: 13892340
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of live poliovirus vaccine.
    BURNEY LE
    J Am Med Assoc; 1959 Dec; 171():2180-1. PubMed ID: 13806224
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of live attenuated poliovirus vaccine.
    SKINNER RG
    J Fla Med Assoc; 1960 May; 46():1387-9. PubMed ID: 13831482
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurement of the protective effect of attenuated poliovirus vaccine.
    KNOWELDEN J; HALE JH; GARDNER PS; LEE LH
    Br Med J; 1961 May; 1(5237):1418-20. PubMed ID: 13757211
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral, live poliovirus vaccine for elimination of poliomyelitis.
    SABIN AB
    Arch Intern Med; 1960 Jul; 106():5-9. PubMed ID: 14440554
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunization with live attenuated poliovirus vaccine.
    KRUGMAN S; WARREN J; EIGER MS; BERMAN PH; MICHAELS RM; SABIN AB
    Am J Dis Child; 1961 Jan; 101():23-9. PubMed ID: 13754588
    [No Abstract]   [Full Text] [Related]  

  • 16. Properties and behavior of orally administered attenuated poliovirus vaccine.
    SABIN AB
    J Am Med Assoc; 1957 Jul; 164(11):1216-23. PubMed ID: 13438685
    [No Abstract]   [Full Text] [Related]  

  • 17. Proposed method and evaluation of the monkey neurovirulence test for attenuated poliovirus vaccine.
    JUNGHERR EL; CABASSO VJ; MOYER AW; COX HR
    J Infect Dis; 1961; 108():247-61. PubMed ID: 13791071
    [No Abstract]   [Full Text] [Related]  

  • 18. Status of field trials with an orally administered, live attenuated poliovirus vaccine.
    SABIN AB
    J Am Med Assoc; 1959 Oct; 171():863-8. PubMed ID: 14440556
    [No Abstract]   [Full Text] [Related]  

  • 19. Attenuated type 1 poliovirus vaccine; its capacity to infect and to spread from vaccinees within an institutional population.
    HORSTMANN DM; NIEDERMAN JC; PAUL JR
    J Am Med Assoc; 1959 May; 170(1):1-8. PubMed ID: 13640973
    [No Abstract]   [Full Text] [Related]  

  • 20. The PRESENT status of oral live poliovirus vaccines.
    Can Med Assoc J; 1960 Sep; 83(11):606-7. PubMed ID: 13856943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.